Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPISTOP: Nintedanib for Epistaxis in Hereditary Hemorrhagic Telangiectasia
NCT04976036Phase 2Recruiting
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) and epistaxis comparing Nintedanib with Placebo (2 arms). Primary endpoint: Change of epistaxis duration at 7 weeks. Started May 2022; status: recruiting.
02
Drugs
nintedanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on NCT04976036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976036.